# Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

> **NCT05654194** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine Combined With Venetoclax and ATRA group

## Key facts

- **NCT ID:** NCT05654194
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-31
- **Primary completion:** 2023-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05654194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05654194, "Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05654194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*